CVS Health (NYSE:CVS) Downgraded by Vetr to “Hold”

Vetr lowered shares of CVS Health (NYSE:CVS) from a buy rating to a hold rating in a research note issued to investors on Thursday, January 4th. Vetr currently has $77.11 price target on the pharmacy operator’s stock.

A number of other analysts have also commented on CVS. ValuEngine lowered CVS Health from a buy rating to a hold rating in a report on Sunday, December 31st. Royal Bank of Canada started coverage on CVS Health in a report on Tuesday, September 19th. They issued an outperform rating and a $95.00 target price for the company. Jefferies Group set a $86.00 price objective on CVS Health and gave the stock a hold rating in a report on Wednesday, October 18th. Robert W. Baird set a $77.00 price objective on CVS Health and gave the stock a hold rating in a report on Monday, December 4th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $85.00 price objective (down previously from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. CVS Health presently has a consensus rating of Buy and a consensus price target of $87.49.

CVS Health (NYSE CVS) traded up $0.43 on Thursday, hitting $82.01. The stock had a trading volume of 5,773,056 shares, compared to its average volume of 8,270,000. The stock has a market cap of $83,080.00, a PE ratio of 16.94, a PEG ratio of 1.28 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.00.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.64 earnings per share. sell-side analysts predict that CVS Health will post 5.88 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 annualized dividend and a yield of 2.44%. CVS Health’s payout ratio is currently 41.32%.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.61% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVS. Pathstone Family Office LLC grew its stake in CVS Health by 341.0% in the second quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after purchasing an additional 982 shares in the last quarter. Wealthcare Advisory Partners LLC grew its stake in CVS Health by 330.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares in the last quarter. Fieldpoint Private Securities LLC grew its stake in CVS Health by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI grew its stake in CVS Health by 119.6% in the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares in the last quarter. Finally, MPS Loria Financial Planners LLC bought a new position in CVS Health in the second quarter worth approximately $119,000. 81.70% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “CVS Health (NYSE:CVS) Downgraded by Vetr to “Hold”” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/28/vetr-downgrades-cvs-health-cvs-to-hold.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply